PDL BioPharma asked XVIVO to show how a novel humanized antibody, HuLuc 63, appears to induce anti-tumor effects by binding to a protein expressed only on the surface of myeloma cells. This initiates antibody-dependent cytotoxic activity which targets myeloma cells while leaving healthy cells intact.
CEO, Threshold Pharmaceuticals
I reviewed the video this morning and think it looks truly exceptional. I had high expectations to begin with and you have actually exceeded them.